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ABSTRACT
Objectives: To compare the cost-effectiveness of
PhysioDirect with usual physiotherapy care for patients
with musculoskeletal problems.
Design: (1) Cost-consequences comparing cost to the
National Health Service (NHS), to patients, and the
value of lost productivity with a range of outcomes.
(2) Cost-utility analysis comparing cost to the NHS
with Quality-Adjusted Life Years (QALYs).
Setting: Four physiotherapy services in England.
Participants: Adults (18+) referred by their general
practitioner or self-referred for physiotherapy.
Interventions: PhysioDirect involved telephone
assessment and advice followed by face-to-face care if
needed. Usual care patients were placed on a waiting
list for face-to-face care.
Primary and secondary outcomes: Primary clinical
outcome: physical component summary from the
SF-36v2 at 6 months. Also included in the cost-
consequences: Measure Yourself Medical Outcomes
Profile; a Global Improvement Score; response to
treatment; patient satisfaction; waiting time. Outcome
for the cost-utility analysis: QALYs.
Results: 2249 patients took part (1506 PhysioDirect;
743 usual care). (1) Cost-consequences: there was no
evidence of a difference between the two groups in the
cost of physiotherapy, other NHS services, personal
costs or value of time off work. Outcomes were also
similar. (2) Cost-utility analysis based on complete
cases (n=1272). Total NHS costs, including the cost of
physiotherapy were higher in the PhysioDirect group
by £19.30 (95% CI −£37.60 to £76.19) and there was
a QALY gain of 0.007 (95% CI −0.003 to 0.016). The
incremental cost-effectiveness ratio was £2889 and the
net monetary benefit at λ=£20 000 was £117 (95% CI
−£86 to £310).
Conclusions: PhysioDirect may be a cost-effective
alternative to usual physiotherapy care, though only
with careful management of staff time. Physiotherapists
providing the service must be more fully occupied than
was possible under trial conditions: consideration
should be given to the scale of operation, opening
times of the service and flexibility in the methods used
to contact patients.
INTRODUCTION
There is a trend to explore the use of new
technology in the delivery of healthcare, par-
ticularly the use of telephone assessment and
triage as, for example, in National Health
Service (NHS) Direct.1 These services aim to
better manage patient demand, and research
has shown that telephone-based services can
be safe, clinically accurate, cost-effective,
acceptable to patients and reduce the work-
load of clinicians,2–5 although there have
been some concerns about using telephone
triage in patients presenting with acute
health problems.6
Musculoskeletal pain problems are one of
the most common causes of disability. Over a
quarter of all patients registered in general
practice will consult at least once for a muscu-
loskeletal problem each year,7 8 with musculo-
skeletal pain accounting for around 15% of
all general practitioner (GP) consultations.9
This high prevalence of musculoskeletal
ARTICLE SUMMARY
Strengths and limitations of this study
▪ Findings are based on a large sample of patients
with a wide range of musculoskeletal problems
based in diverse locations.
▪ The study takes a broad perspective, including
the healthcare provider, patients and a valuation
of lost productivity.
▪ Physiotherapists were constrained by trial condi-
tions and were underutilised.
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problems10 results in large direct and indirect healthcare
costs: for example, low back pain alone has recently been
estimated to cost the UK economy £15.84 billion a
year.11 12 Most patients are managed with advice and anal-
gesia but many are referred to physiotherapists, with 1.23
million new referrals each year from GPs and 4.4 million
in total.13 Ensuring timely access to physiotherapy has
long been an issue within the UK NHS, with waiting
times of more than 4 months in some areas. Patients may
suffer unnecessary pain and disability, and there are high
productivity losses: for example, back pain accounts for
some 120 million days of certiﬁed absence from work
each year.14 Delay may also cause NHS inefﬁciencies on
the one hand as some patients recover and do not attend
their physiotherapy appointment when it ﬁnally arrives,
while on the other, some patients continue to access
more expensive forms of treatment while awaiting their
appointment.
In response to these problems, physiotherapy services
have drawn on the new service models and a range of
‘PhysioDirect’ services have been developed. These vary
in format though they commonly involve a physiotherap-
ist assessing a patient’s musculoskeletal pain problem
over the telephone, sometimes supported by compu-
terised assessment templates, offering tailored, self-
management advice supplemented by written advice
sent by post. Alternatively if the assessment ﬁndings
suggest that face-to-face care is needed this is arranged,
and patients who are initially managed by telephone
advice can call back for further advice and/or
face-to-face treatment.15 There is, however, limited evi-
dence about the costs and beneﬁts of this approach
within physiotherapy. Local evaluations and non-
randomised studies suggest that these services may be
popular with patients16–18 and diagnoses made by phy-
siotherapists over the telephone are comparable to diag-
noses reached in face-to-face assessments19–21 although
there is some concern that the experience of the physio-
therapist providing the telephone assessment might be
important.19 22
In particular there is no information about the costs
or cost-effectiveness of PhysioDirect services, despite: (1)
a major underlying rationale for their development
being to generate greater efﬁciency in the use of
resources; and (2) a ready presumption that telephone-
based services result in lower costs (by assuming that ser-
vices better use physiotherapy time, use less costly tele-
phone consultations and reduce rates of appointment
non-attendance). Without such evidence, preferably gen-
erated alongside high-quality primary evidence obtained
using rigorous study designs, it remains unclear whether
such services should be more widely implemented. This
paper reports the results of an economic evaluation con-
ducted alongside a randomised controlled trial powered
to generate evidence on whether PhysioDirect services
for primary care patients with musculoskeletal problems
produce equivalent outcomes to usual face-to-face
services.
METHOD
Study design
We conducted an economic evaluation alongside a ran-
domised controlled trial to establish the cost-
effectiveness of PhysioDirect compared with usual care
based only on face-to-face treatment over a period of
6 months. The trial and its clinical ﬁndings have been
reported in full elsewhere.15 23 The aim of the evalu-
ation was to provide information about the long-run
costs and beneﬁts of the alternative methods of running
a physiotherapy service for this patient group so with
that in mind we excluded the initial set up costs asso-
ciated with establishing the new telephone service,
including the training undertaken by the practitioners.24
As the nature of the intervention suggests there could
be an impact on patients’ costs, and as it is known that
musculoskeletal conditions account for a considerable
amount of time off work14 we chose to use a cost-
consequences approach, comparing cost from all three
perspectives (healthcare provider, patients and carers,
lost productivity) with a range of clinical outcomes.25 26
However, the perspective of greatest interest to the UK
policy makers is that of the health and social care pro-
vider27 so we also conducted a cost-utility analysis to
compare cost to the NHS with Quality-Adjusted Life
Years (QALYs).
Setting and participants
We recruited adults aged 18 and over from four commu-
nity physiotherapy services in England—Bristol,
Somerset, Stoke-on-Trent and Cheshire—which provided
diversity in terms of socioeconomic status and a mix of
urban and rural communities. All patients referred by
their GP, or who referred themselves, for physiotherapy
for a non-urgent musculoskeletal problem were invited
to take part. Patients were randomised to PhysioDirect
or usual care on a two to one basis to increase the
chances of the PhysioDirect service being fully utilised.
Interventions
The intervention has been reported in detail else-
where.15 23 Patients randomised to the PhysioDirect
service received an invitation to telephone a senior
(band 6 or above) specially trained physiotherapist, who
assessed their musculoskeletal problem with the aid of
previously developed computerised templates.23 These
templates were provided by Huntingdonshire Primary
Care Trust, which has been operating a similar service
since 2001. Patients were then sent appropriate advice
leaﬂets about self-management and exercises to try at
home, and invited to phone again and/or make a
face-to-face appointment if necessary. If the service was
engaged when the patient called, the call was answered
by a receptionist who added the patient to a ‘call-back’
list and the physiotherapist would return the call when
they were free. Patients randomised to usual care were
put on the usual service waiting list for face-to-face
assessment and treatment.
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Outcome measures
We used the EQ-5D-3L28 valued using the UK tariff,29 to
estimate QALYs gained for the cost-utility analysis. The
primary outcome for the trial was the physical compo-
nent summary (PCS) measure from the SF-36v2 ques-
tionnaire30 and secondary clinical outcomes included:
the Measure Yourself Medical Outcomes Proﬁle
(MYMOP)31; a Global Improvement Score—a single
question about overall improvement; a composite
measure of response to treatment including pain, func-
tion and overall improvement (OMERACT OARSI);32
patient satisfaction and waiting time to ﬁrst treatment
advice from a physiotherapist. All outcomes (except the
global improvement score and waiting time to ﬁrst treat-
ment advice) were measured at baseline, 6 weeks and
6 months and were obtained from a self-completed ques-
tionnaire administered at these three time points.
Resource use
The analysis was based on costs related to the reason for
which the patient was referred to the physiotherapy
service. We identiﬁed relevant resources in discussion
with participating physiotherapists and service managers.
Direct costs to the healthcare provider included: cost of
initial and follow-up physiotherapy consultations;
primary and community consultations; hospital care and
prescribed medication. Patient and carer costs included:
telephone calls to the PhysioDirect service; travel;
over-the-counter medication; prescription costs; private
therapy and purchase of equipment; extra domestic
help and loss of earnings. Lost productivity was esti-
mated separately in relation to time off work to attend
physiotherapy appointments and time off because of the
musculoskeletal condition itself.
Patient level data about all physiotherapy appoint-
ments and consultations were recorded either automatic-
ally by computer or by the physiotherapist treating the
patient. For those in the intervention group, the
PhysioDirect assessment software recorded which physio-
therapist conducted each telephone call, and the dur-
ation of each call. In addition to the time logged on to
the system physiotherapists had to carry out administra-
tive activities following each telephone call, such as col-
lating information to send to the patient by post. The
time spent on these activities was estimated from infor-
mation available at one site (Bristol) where manual
recording of the entire encounter supplemented the
electronic recording.
Physiotherapists assigned to the PhysioDirect service
were required to be available throughout the time the
service was ‘open’ but they were not usually fully
engaged in dealing with patients in the PhysioDirect
service during these hours. We conducted an observa-
tional time and motion study at each of the four sites to
determine how they occupied their non-PhysioDirect
contact time in order to apportion costs appropriately.
Time and motion data were collected at points in the
study when the sites were expected to be fully
operational, and across a mix of day, time of day and
location. The capital costs required to run a telephone
service are potentially less than for a face-to-face service.
Each site provided information about space and equip-
ment required to run their telephone service and we
used this to estimate an overall percentage reduction of
capital costs for these compared with a standard
face-to-face service.
Data about all face-to-face appointments were recorded
routinely. These data included the length of appoint-
ment, the grade of the physiotherapist seen, and informa-
tion about missed appointments.
Information about other NHS resource use was col-
lected, where possible, from general practice records
and supplemented by information gained directly from
patients. General practice notes were scrutinised for
patient level data on primary care consultations and pre-
scribed medication. We included all consultations at
which musculoskeletal condition for which the patient
was referred to physiotherapy was mentioned and these
were recorded by type of consultation (eg, face-to-face,
telephone, out of hours, home visit) and by type of pro-
fessional seen (eg, GP, nurse). It was not feasible to dis-
tinguish between medication prescribed for the
condition for which the patient was referred to physio-
therapy and any other musculoskeletal problem so we
included all medication of a potentially relevant type,
deﬁned using British National Formulary (BNF)33
coding. These were: analgesics (chapters 4.7.1–4.7.2);
non-steroidal anti-inﬂammatory drugs (10.1.1); local cor-
ticosteroid injections (10.1.2.2) and drugs for the relief
of soft-tissue inﬂammation (10.3).
A questionnaire was administered to participants at
6 weeks and 6 months after randomisation to obtain
resource use data not available elsewhere. The question-
naire was designed speciﬁcally for this study but was
similar in content and structure to others used for the
same purpose.34 Questions included information about
hospital care related to the condition for which the
patient was referred to physiotherapy: visits to accident
& emergency, outpatient appointments, and inpatient
stays. Information about personal expenditure relevant
to the patient’s musculoskeletal condition was also
gained from the questionnaire at 6 weeks and 6 months.
We asked about the cost of travel to physiotherapy and
other healthcare appointments, expenditure on
over-the-counter medication, prescription costs, use of
private therapies and their cost, expenditure on equip-
ment or devices and extra help at home. In addition,
participants were asked about any time off work, and the
associated loss of earnings, because of their condition or
to attend healthcare appointments relating to the condi-
tion including usual care physiotherapy and
PhysioDirect.
Valuation of resource use
Table 1 gives the unit costs and sources used to value
the healthcare resources. We used Curtis35 to value
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primary and community healthcare and Department of
Health reference costs36 for all hospital-based care. The
cost of prescribed medication was estimated from that
published in the BNF,33 adjusted to allow for the dis-
count available to the NHS, and the professional fee
and container allowance in accordance with the Drug
Tariff for England.37 Personal expenditure was reported
directly by the participants, the exception being travel by
car, which was reported as mileage and costed using the
AA schedule of motoring costs.38 Time off work was
valued using the median gross weekly earnings by age
and sex.39
The cost of face-to-face physiotherapy consultations was
estimated by adapting the methods of Curtis35 to obtain a
different unit cost for each band of staff at each site.
National median pay rates, by band,42 were adjusted to
allow for National Insurance, superannuation, and over-
heads, as per Curtis, then further adjusted to allow for
band and site-speciﬁc non-contact time. Information about
the proportion of time physiotherapists on each grade typ-
ically spend in direct contact with patients was provided by
the four physiotherapy service managers. This provided us
with a cost per hour for each band of staff at each site.
The unit cost of physiotherapists working in the
PhysioDirect service was estimated in a similar way, but
allowing for the reduced cost of capital and overheads;
information from the site managers indicated this to be
about 50%. To obtain a cost per hour of telephone
contact we used information from the computerised
records of the PhysioDirect service, which identiﬁed the
proportion of time spent by physiotherapists actually
dealing with patients in the PhysioDirect service. We
then combined this with data from the time and motion
study, which identiﬁed activities undertaken during non-
contact time, for example, administration relating to
face-to-face appointments or general administration, to
give a cost per hour for each band of staff at each site.
All costs were valued in £ sterling at 2009 prices,
adjusted for inﬂation where necessary.35
Data analysis
We investigated the amount of each resource used by
patients in each group using frequencies, means and
medians. Mean total cost per participant was derived by
combining resource use with unit costs.
QALYs were derived from responses to the EQ-5D-3 L
at baseline, 6 weeks and 6 months using valuations from
the UK general population.29 These values, representing
health-related quality of life on a scale between 0
(death) and 1 (best imaginable health), were used to
compute QALYs experienced over the 6-month period
using the area under the curve approach and adjusting
for any difference between the groups at baseline.43
A cost-consequences matrix was constructed using all
available data. We compared costs from all three per-
spectives (healthcare provider, patients and carers, lost
productivity) with the SF-36v2 PCS, MYMOP, Global
Improvement Score, OMERACT OARSI, patient satisfac-
tion, waiting time and QALYs.
The cost-utility analysis was carried out using data on
all patients for whom we had complete NHS cost and
QALY data. An incremental cost-effectiveness ratio
(ICER) was constructed, comparing the difference in
mean total cost per patient with mean difference in
QALYs, thus the lower the ICER, the greater the cost-
effectiveness and the better the value for money.
Table 1 Data sources and unit costs
Unit cost (£)
Primary and community care35
General practitioner
Surgery 27.00
Telephone consultation 16.00
Home visit 91.00
Practice nurse
Surgery 10.00
Telephone consultation 5.93
Healthcare assistant/phlebotomist
Surgery 6.92
District nurse
Home visit 16.33
Out of hours40 41
General practitioner 23.50
Hospital care36
A&E 103.00
Outpatient visits By Healthcare Resource Group, differentiated by first and follow-up
Inpatient stays By Healthcare Resource Group
Prescribed medication33 per item, by name, strength and amount
Mileage38 0.4612
Time off work39 Median national wage by age and sex
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Uncertainty around the ICER was captured using the
bootstrapping technique: 5000 replicates of the cost and
QALY data were created by sampling from the original
data, with replacement. The range and spread of the
5000 ICERs was used to construct a cost-effectiveness
acceptability curve (CEAC) to indicate the likelihood of
the intervention being cost-effective. The net monetary
beneﬁt (NMB) of the intervention was estimated from
the point estimate of the ICER for values of societal
willingness-to-pay of £20 000 and £30 000/QALY. If the
NMB is positive at a given level of willingness to pay, the
intervention is regarded as cost-effective. CIs around the
NMB were formed from the bootstrapped estimates.
We used the multiple imputation by chained equation
procedure to address the issue of missing cost and
EQ-5D data.44 This technique uses a regression model to
estimate missing values from known values. In addition
to cost and EQ-5D-3 L variables the imputation model
also included randomisation group, age, sex and SF36v2
PCS. Stata V.1245 was used to generate ﬁve datasets using
10 switching procedures.
Discounting was not carried out because the analysis
was restricted to costs and outcomes over a period of
less than a year. All analyses were conducted using
Microsoft Excel and Stata V.12.45
Sensitivity analyses
We addressed three areas of uncertainty using four one/
two-way sensitivity analyses. First, we estimated the cost of
running the PhysioDirect service if it was operating at
full capacity. It is likely that this was not achieved during
the trial because of low demand due to exclusions and
non-participation in the trial; inﬂexible stafﬁng levels to
ensure consistency throughout the trial period; and the
‘one-way’ system generally used, where physiotherapists
waited for patients to call them but did not routinely
contact patients themselves (notwithstanding some
limited use of answer-machines). Data from the Bristol
service, which continued to operate beyond the trial
period and was then able to tailor stafﬁng levels to
demand, were used to estimate the cost of running a
more ‘efﬁcient but feasible’ PhysioDirect service once
the trial had ended.
The second area of uncertainty addressed hospital
costs. Patients in the trial were recruited from primary
care and for these, use of secondary care is infrequent
but relatively expensive and this can have a dispropor-
tionate effect on mean total cost. We tested this by
excluding hospital costs from the total.
The third area of uncertainty tested the effect of using
imputed data rather than complete cases; the third sen-
sitivity analysis used trial data with missing values
imputed.
Finally, in a two-way sensitivity analysis, we re-estimated
the results of the ﬁrst, (mimicking an ‘efﬁcient but feas-
ible’ service) in this instance using the imputed dataset.
RESULTS
A total of 2249 patients were recruited between July and
December 2009, and followed up until June 2010, 1506
allocated to PhysioDirect and 743 to usual care. The
mean age was 60, with slightly more women than men
(60% vs 40%); they were overwhelmingly white (97%),
just over half (60%) were employed and all but a few
were referred for physiotherapy by their GP. Lower limb
problems were the most prevalent (30%) reason for
referral, 27% patients had a lumbar problem and 23%
upper limb problems. Nearly all participants
(2223=99%) gave permission to access their GP notes to
obtain data about primary care encounters and pre-
scribed medication. Eighty-one per cent returned ques-
tionnaires at both 6 weeks and 6 months though not all
participants completed all sections at both time points.
We had complete NHS cost and QALY data for 840
(56%) PhysioDirect and 432 (58%) usual care
participants.
Resource use
Table 2 gives information about the different types of
physiotherapy consultations by patients in each group.
Of the 1506 patients in the PhysioDirect group, 39%
(586) were managed solely over the telephone and only
Table 2 Number of physiotherapy consultations and mean duration, by type and group
Usual care (n=743) PhysioDirect (n=1506)
Face-to-face appointments
Mean (SD) number 3.11 (2.63) 1.91 (2.72)
Mean (SD) total duration (minutes) 107.51 (88.92) 64.20 (89.31)
Telephone appointments
Mean (SD) number 0.13 (0.44) 0.96 (0.63)
Mean (SD) total duration (minutes) 4.21 (14.64) 27.37 (19.92)
Home visits
Mean (SD) number 0.00 (0.06) 0.00 (0.06)
Mean (SD) total duration (minutes) 0.14 (2.27) 0.12 (2.12)
All physiotherapy contacts
Mean (SD) number 3.25 (2.70) 2.87 (2.94)
Mean (SD) total duration (minutes) 111.86 (90.50) 91.70 (95.40)
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46% (695) had any face-to-face consultations. In total,
patients in the usual care group had, on average, 0.38
(95% CI 0.12 to 0.63) more consultations than those in
the PhysioDirect group and the mean total duration of
all consultations was 20 min longer (95% CI 12 to 28).
Tables 3 and 4 give information about NHS and per-
sonal resource use. Just over a third of patients (35%)
had a GP consultation during the 6 months and 40%
received a prescription for musculoskeletal pain-related
medication. There was very little difference between the
two groups in terms of healthcare use and the only
notable difference in personal expenditure was travel to
physiotherapy appointments.
Costs and consequences
Table 5 summarises the mean cost per patient, by group,
for each category of cost. All available data are included
giving variable denominators for each category.
Comparing the two groups, there are small differences
in cost in some categories but for most of these the CIs
indicate that there is no evidence of a difference
between the groups.
Table 6 combines the results of the cost analysis with
the full range of primary and secondary outcomes,
including QALYs.
Results are presented for all available data, with cost
categories combined. Denominators vary within the
table and they also differ from those in table 5 because
subcategories have been collapsed. There was no evi-
dence of a difference in the primary clinical outcome
(the SF36v2 PCS) between the groups, suggesting that
PhysioDirect led to similar outcomes as usual physiother-
apy care. Patients in the PhysioDirect group had their
ﬁrst assessment and telephone advice 27 days earlier
than those in the usual care group, however patient satis-
faction was slightly lower in those receiving PhysioDirect.
QALYs were higher in the PhysioDirect group by 0.009,
which equates to about 3.3 extra days of full health over
a year.
Cost-utility analysis
The cost-utility analysis presented in table 7 uses com-
plete cases, that is, we include only those patients for
whom we had complete NHS cost and QALY data: 432
(58%) from the usual care group and 840 (56%) from
PhysioDirect. The small extra cost of caring for patients
in the PhysioDirect group was compensated for by the
extra QALY gain, giving an ICER of £2889. Values below
£20 000 are regarded by National Institute for Health
and Care Excellence (NICE) to indicate a cost-effective
intervention.27 At this threshold level of willingness to
pay for a QALY there is a positive NMB of £117 (95% CI
−£96 to £310) and there is 0.88 probability that the
Table 3 Health services resource use, by group
Mean (SD) number of consultations
n Usual care n PhysioDirect
GP consultations 739 0.77 (1.47) 1484 0.87 (1.68)
Nurse consultations 739 0.04 (0.22) 1484 0.06 (0.32)
Other primary care consultations 739 0.02 (0.14) 1484 0.02 (0.17)
Total number of primary care contacts 739 0.83 (1.56) 1484 0.96 (1.84)
Number of prescriptions 728 1.36 (2.73) 1469 1.68 (3.72)
A&E (visits) 467 0.02 (0.01) 912 0.03 (0.01)
Outpatient (consultations) 467 0.17 (0.83) 910 0.35 (1.03)
Inpatient stays (finished consultant episodes) 465 0.01 (0.10) 910 0.01 (0.10)
All available data.
Table 4 Patient and societal resource use, by group
Number (%) reporting n Usual care n PhysioDirect
Expenditure on travel to physiotherapy 462 242 (52.4) 1232 308 (25.8)
Expenditure on travel to primary care 669 116 (17.3) 1337 237 (17.7)
Expenditure on over-the-counter medication 506 256 (50.6) 1028 512 (49.8)
Expenditure on prescriptions 559 264 (47.2) 1085 508 (46.8)
Expenditure on private therapy 484 89 (18.4) 934 167 (17.9)
Equipment purchase 480 139 (29.0) 939 233 (24.8)
Payments for extra domestic help 459 35 (7.6) 928 76 (8.2)
Loss of earnings 598 30 (5.5) 1209 64 (5.3)
Any time off to attend physiotherapy consultation 692 218 (31.5) 1416 380 (26.8)
Work has been affected because of condition 477 141 (29.6) 959 317 (33.1)
All available data.
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intervention is cost-effective. This is illustrated in the
CEAC in ﬁgure 1.
Sensitivity analysis
The results of the four sensitivity analyses are shown in
table 8 and ﬁgure 2. Scenario (1) indicates the potential
cost-effectiveness of a more efﬁcient PhysioDirect
service. During the trial PhysioDirect clinic opening
hours, physiotherapists spent about 35% of their time
on the phone or dealing with directly related administra-
tion; in Bristol after the trial, this was increased to 57%.
Under this scenario, the cost per patient in the
PhysioDirect group was £14.53 less than under trial con-
ditions and £2.11 less per patient in the usual care
group. The ICER is therefore lower at £1045, while the
NMB is correspondingly higher at £127 (λ=£20 000). At
low levels of λ, the probability of PhysioDirect being cost-
effective under this scenario is higher than with the base
case, though at λ=£20 000 it reaches a similar value (see
ﬁgures 1 and 2).
The effect of removing hospital costs from the analysis
is shown in sensitivity analysis (2). Hospital costs
accounted for 75% of all NHS costs yet only 19%
(n=252) participants reported using any secondary care.
Hospital use was evenly divided between the two groups
so removing these from the analysis made very little dif-
ference to incremental analysis.
The effect of imputing missing NHS cost and QALY
data is explored in sensitivity analysis (3). Using these
data the cost of the interventions is lower but this is
offset by higher NHS costs, giving a higher mean total
cost in both groups, by £21.41 in the usual care group
and £6.58 in the PhysioDirect group. QALYs using
imputed data are lower, by 0.005 in the usual care group
and by 0.010 in the PhysioDirect group. The net effect is
a reduction of both incremental cost and incremental
QALYs, giving an ICER of £2260. Uncertainty around
the ICER is reduced, as seen by the ﬂatter CEAC in
ﬁgure 2.
Sensitivity analysis (4) combines analyses (1) and (3)
by using imputed cost data in the ‘efﬁcient service’
Table 5 Mean total cost per patient, by group and category. All available data*
Usual care PhysioDirect Incremental difference
(95% CI)n Mean (SD) cost n Mean (SD) cost
Physiotherapy services
Face-to-face appointments 743 £64.42 (£53.00) 1506 £38.76 (£53.92) −£25.66 (−£30.37 to −£20.95)
Telephone appointments 743 £5.22 (£18.01) 1506 £35.17 (£26.34) £29.94 (£27.84 to £32.05)
Home visits 743 £0.08 (£1.33) 1506 £0.08 (£1.46) £0.00 (−£0.12 to £0.13)
Total physiotherapy cost 743 £69.73 (£56.17) 1506 £74.01 (£63.97) £4.28 (−£1.12 to £9.69)
Primary care services
GP consultations 739 £19.21 (£35.91) 1484 £21.69 (£41.66) £2.48 (−£1.04 to £6.00)
Nurse consultations 739 £0.44 (£2.37) 1484 £0.61 (£3.17) £0.16 (−£0.10 to £0.42)
Other primary care consultations 739 £0.03 (£0.57) 1484 £0.07 (£1.31) £0.05 (−£0.05 to £0.15)
Total primary care cost 739 £19.68 (£36.68) 1484 £22.37 (£42.83) £2.69 (−£0.92 to £6.30)
Medication cost 728 £11.04 (£51.61) 1469 £10.33 (£55.43) −£0.72 (−£5.53 to £4.10)
Hospital services
A&E 467 £1.99 (£17.12) 912 £3.17 (£20.84) £1.18 (−£1.01 to £3.37)
Outpatient 467 £30.74 (£98.36) 910 £38.35 (£126.05) £7.61 (−£5.50 to £20.72)
Inpatient 465 £51.02 (£520.48) 910 £34.99 (£399.62) −£16.03 (−£65.70 to £33.64)
Total hospital cost 459 £83.04 (£561.68) 899 £77.00 (£446.24) −£6.04 (−£60.99 to £48.91)
Personal expenditure
Cost of all calls to physiotherapy
service
743 £0.97 (£0.99) 1506 £1.75 (£1.29) £0.79 (£0.68 to £0.89)
Travel to physiotherapy 462 £6.11 (£11.48) 1232 £3.11 (£8.51) −£3.01 (−£4.01 to −£2.00)
Travel for primary care 669 £0.65 (£2.93) 1337 £0.75 (£4.10) £0.11 (−£0.24 to £0.45)
Over-the-counter medication 490 £7.67 (£14.09) 987 £8.61 (£22.38) £0.94 (−£1.23 to £3.11)
Cost of prescriptions 553 £2.72 (£8.95) 1076 £2.67 (£8.33) −£0.05 (−£0.93 to £0.82)
Private therapy 475 £21.98 (£70.34) 915 £39.34 (£296.94) £17.36 (−£9.76 to £44.48)
Equipment purchase 473 £17.16 (£169.12) 924 £9.12 (£56.42) −£8.04 (−£20.08 to £4.00)
Extra domestic help 451 £10.93 (£64.31) 905 £13.68 (£96.02) £2.75 (−£7.07 to £12.56)
Cost associated with loss of
earnings
598 £46.69 (409.72) 1209 £82.78 (£885.85) £36.09 (−£38.63 to £110.81)
Value of time off work
Time off work to attend
physiotherapy
598 £12.90 (£38.99) 1211 £11.91 (£57.86) £0.95 (−£3.81 to £5.70)
Time off work associated with the
condition
452 £265.92 (£1350.82) 884 £226.61(£1139.84) £111.31 (−£159.04 to £379.67)
*Uses all available data, so denominators differ by category.
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Table 6 Cost-consequences. All available data*
n (%) Usual care n (%) PhysioDirect Incremental difference (95% CI)
Mean (SD) cost
Total physiotherapy cost 743 £69.73 (£56.17) 1506 £74.01 (£63.97) £4.28 (−£1.12 to £9.69)
Cost of NHS services including physiotherapy 453 (61%) £189.19 (£557.61) 888 (59%) £196.43 (£472.02) £7.24 (−£49.68 to £64.10)
Total personal expenditure 310 (42%) £121.10 (£575) 714 (47%) £166.40 (£1040.27) £45.30 (−£78.01 to £168.61)
Total value of all time off work† 451 (61%) £276.75 (£1355.00) 883 (59%) £240.74 (£1147.20) −£36.01 (−£174.69 to £102.66)
Consequences‡ Difference/OR (95% CI)§
SF36v2 PCS 629 (85%) 44.18 (10.84) 1283 (85%) 43.50 (10.94) −0.01 (−0.80 to 0.79)
MYMOP¶ 518 (70%) 2.40 (1.38) 1033 (69%) 2.40 (1.43) −0.02 (−0.16 to 0.11)
Global improvement score 501 (67%) 4.07 (1.40) 1001 (66%) 4.01 (1.44) −0.08 (−0.23 to 0.08)
Response to treatment (OMERACT OARSI) 510 (69%) 197 (38.6%) 1029 (68%) 430 (41.8%) 1.14 (0.92 to 1.43)
Waiting time to first assessment and advice 618 (83%) 34 (20 to 55)** 1281 (85%) 7 (4 to 15)** 0.32 (0.29 to 0.35)††
Patient overall satisfaction 367 (49%) 79.7 (26.5) 739 (49%) 75.9 (28.3) −3.8 (−7.3 to −0.3)
QALYs‡‡ 454 (61%) 0.322 (0.079) 881 (58%) 0.331 (0.082) 0.009 (−0.000 to 0.018)
*Uses all available data, so denominators differ by category.
†Total of time off to attend physiotherapy and associated with the condition.
‡At 6-month follow-up time point.
§Adjusted for outcome at baseline, gender, age, referral problem, PCT.
¶Lower score is better.
**Median (IQR).
††Accelerated failure time analysis.
‡‡Adjusted for outcome at baseline.
MYMOP, measure yourself medical outcomes profile; NHS, National Health Service; PCS, physical component summary; QALY, Quality-Adjusted Life Year.
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scenario. In this case the results indicate that
PhysioDirect is, on average, cheaper than usual care with
a possible saving of £6.02/patient, which gives a negative
value for the ICER, indicating the intervention is super-
ior in terms of both cost and outcome. The probability
that the service is cost-effective at λ=£20 000 is 0.72.
DISCUSSION
Statement of principal findings
The results of this economic evaluation suggest that
PhysioDirect services for patients with musculoskeletal
problems require careful management if they are to be a
cost-effective alternative to usual physiotherapy care.
There was very little difference between the two groups
in terms of either outcomes or costs, and the ﬁnding
that PhysioDirect is cost-effective is based on evidence
that it provides very slightly greater QALY beneﬁts at
very slightly greater cost.
Clearer cost savings were observed in the sensitivity
analysis that replicated the post-trial service, once
greater ﬂexibility in working arrangements was imple-
mented. Without the restrictions of a trial environment
stafﬁng was adjusted to meet the anticipated demand, a
call-back service was employed which accommodated
ﬂuctuations in activity during each session, referrals
added to the system were adjusted regularly to reﬂect
actual stafﬁng and the number of patients waiting for a
call-back and a higher throughput of patients led to
greater economies of scale. These changes ensured phy-
siotherapists within the PhysioDirect service spent a
higher proportion of their PhysioDirect clinic time on
the telephone with patients. There was no evidence of a
difference between PhysioDirect and usual care in cost
to patients and their families, or to society through the
costs of lost production.
Strengths and weaknesses of the study
The study has a number of strengths. It is the ﬁrst study
assessing the cost-effectiveness of a PhysioDirect service
including a large sample of patients with a wide range of
musculoskeletal problems based across a number of
Table 7 Cost-effectiveness analysis
Usual care PhysioDirect Incremental difference
(95% CI)n Mean (SD) cost n Mean (SD) cost
Cost of physiotherapy 432 £78.77 (£57.08) 840 £86.75 (£65.47) £7.98 (£0.69 to £15.27)
Cost of NHS services other than
physiotherapy
432 £100.91 (£502.02) 840 £112.23 (£476.91) £11.32 (−£45.08 to £67.72)
Total cost including physiotherapy 432 £179.68 (£504.73) 840 £198.98 (482.12) £19.30 (−£37.60 to £76.19)
QALYs 432 0.325 (0.077) 840 0.332 (0.081) 0.007 (−0.003 to 0.016)
Incremental cost-effectiveness ratio (ICER) £2889
Median net monetary benefit (95% CI) based on bootstrapped results
λ=£20 000 £117 (−£86 to £310)
Probability of intervention being cost-effective 0.88
λ=£30 000 £184 (−£106 to £461)
Probability of intervention being cost-effective 0.90
Includes cases with complete data on NHS costs and QALYs.
NHS, National Health Service; QALY, Quality-Adjusted Life Year.
Figure 1 Cost-effectiveness
acceptability curve (CEAC)
showing the probability that the
intervention is cost-effective at
different levels of willingness to
pay for one quality-adjusted life
year.
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locations.15 It uses a rigorous study design and conforms
to CONSORT guidelines.46 The follow-up rate from par-
ticipating patients was in line with other primary care
trials,47 48 a high proportion of the resource use data
were collected from GP records, and there was collec-
tion of resource use information outside of the main
health service perspective. The cost consequences ana-
lysis provides complete information on costs from differ-
ent perspectives compared with a range of outcomes so
although this approach is sometimes criticised for
leaving the reader to evaluate the ﬁndings it does have
the advantage of transparency. Furthermore, in this
study we have also presented a cost-utility analysis that
conforms to the recommendations of NICE.
Nevertheless, there are also limitations. The practices
recruited to the trial had a low proportion of ethnic
minority patients, a slightly lower proportion of patients
from deprived areas were judged to be eligible, and the
proportion of eligible individuals consenting to partici-
pate in the trial was only 50%.23 These factors limit the
generalisability of the results though none of these selec-
tion effects was large. Further, a particular difﬁculty in
conducting economic evaluation with new service devel-
opments is ensuring that they are fully utilised,24 particu-
larly when conducting analysis from a long-run
perspective, as here. Although there was a clear run-in
period prior to data collection for the trial (ranging
from 4 to 12 weeks in each of the four sites), to ensure
that services were operating as well as they could, and a
2:1 randomisation ratio in favour of PhysioDirect was
used, there was still considerable underutilisation of the
new service. This was ameliorated by including a more
Table 8 Sensitivity analysis
Usual care PhysioDirect Incremental difference
(95% CI)n Mean (SD) cost n Mean (SD) cost
(1) Mimicking an efficient service
Cost of physiotherapy 432 £76.56 (£55.34) 840 £72.22 (£61.55) −£4.34 (−£11.25 to £2.57)
Cost of NHS services 432 £100.91 (£502.02) 840 £112.23 (476.91) £11.32 (−£45.08 to £67.72
Total cost 432 £177.46 (£504.49) 840 £184.44 (£481.83) £6.98 (−£49.89 to £63.85)
Incremental cost-effectiveness ratio (ICER) £1045
Median net monetary benefit (95% CI) based on bootstrapped results
λ=£20 000 £127 (−£74 to £319)
λ=£30 000 £193 (−£95 to £473)
(2) Excluding hospital costs
Cost of physiotherapy 448 £78.49 (£57.14) 869 £86.84 (£65.25) £8.35 (£1.21 to £15.50)
Cost of NHS services excluding
secondary care
448 £33.75 (£76.46) 869 £33.49 (£63.76) −£0.25 (−£8.05 to £7.54)
Total cost of NHS services including
physiotherapy
448 £112.23 (£99.621) 869 £120.33 (£98.85) £8.10 (−£3.21 to £19.41)
Incremental cost-effectiveness ratio (ICER) £1084
Median net monetary benefit (95% CI) based on bootstrapped results
λ=£20 000 £142 (−£41 to £324)
λ=£30 000 £217 (−£56 to £489)
(3) Imputed data
Cost of physiotherapy 743 £69.73 (£56.17) 1506 £74.01 (£63.97) £4.28 (−£1.12 to £9.69)
Cost of NHS services 743 £131.37 (£465.49) 1506 £131.51 (£384.36) £0.17 (−£36.13 to £36.48)
Total cost of NHS services including
physiotherapy
743 £201.09 (£467.51) 1506 £205.55 (£390.04) £4.46 (−£32.22 to £41.14)
Quality-adjusted life years 743 0.320 (0.003) 1506 0.322 (0.002) 0.002 (−0.006 to 0.009)
Incremental cost-effectiveness ratio (ICER) £2260
Median net monetary benefit (95% CI) based on bootstrapped results
λ=£20 000 £34 (−£119 to £193)
λ=£30 000 £52 (−£172 to £285)
(4) Imputed data and ‘efficient’ service
Cost of physiotherapy 743 £67.61 (£54.19) 1506 £61.41 (£59.13 −£6.20 (−£11.26 to −£1.14)
Cost of NHS services 743 £131.37 (£465.49) 1506 £131.54 (384.36) £0.17 (−£36.13 to £36.48)
Total cost of NHS services including
physiotherapy
743 £198.98 (£467.48) 1506 £192.95 (£389.52) −£6.02 (−£42.68 to £30.63)
Quality-adjusted life years 743 0.320 (0.003) 1506 0.322(0.002) 0.002 (−0.006 to 0.009)
Incremental cost-effectiveness ratio (ICER) −£3054
Median net monetary benefit (95% CI) based on bootstrapped results
λ=£20 000 £47 (−£113 to £202)
λ=£30 000 £67 (−£165 to £293)
NHS, National Health Service.
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fully utilised service within the sensitivity analysis. It
should also be noted that, because of the use of a
long-run perspective in the analysis, set up costs, which
may, in the short-term be important in a ﬁnancially con-
strained service, are not included here. Finally, because
the differences in both costs and effects are small, there
is still some uncertainty around the ﬁndings.
Meaning of the study and implications for policymakers
If the aim of health services is to achieve maximum health
gain from an investment in healthcare, then PhysioDirect
has a high probability of being more cost-effective than
usual physiotherapy care. This research also, however, sug-
gests that it cannot be assumed that PhysioDirect will
reduce costs, although it could potentially do so if
PhysioDirect services are managed efﬁciently. Both the
costs and cost-effectiveness of services will depend on the
productivity of physiotherapist time. If physiotherapists are
able to use most of their time dealing directly with patients
during sessions when they are available on the telephone,
then the service will be less costly. This is most likely to be
achieved by operating a call-back service and/or by operat-
ing the service on a large scale to even out ﬂuctuations in
demand. A larger scale operation might also offer other
economies of scale in terms of infrastructure require-
ments. Further efﬁciencies may also be achieved if these
services are, in the future, provided in conjunction with
direct access for patients (rather than following referral
from another healthcare professional), given that patients
who self-refer are likely to contact the service with muscu-
loskeletal problems of shorter duration,49 and such
patients may be particularly appropriate for the initial
assessment and advice provided by a PhysioDirect service.
More generally, the study has broader implications for tele-
phone services, particularly around the implicit assump-
tion that such services will inevitably be money saving.
Here this assumption was found to be false, largely
because the physiotherapists’ time was underutilised
during PhysioDirect clinic hours. Thus, for all such
services, it will be important for policymakers to ensure
that easy assumptions about the costs of these services are
properly assessed in relation to factors such as how efﬁ-
ciently the service is run, and what proportion of patients
are subsequently invited for face-to-face care following an
initial telephone call.
Unanswered questions and future research
As services evolve, further research should explore the
costs and beneﬁts of PhysioDirect under different scen-
arios. These might include: comparing different skill
levels of staff operating the service; the inclusion of
patient self-referrals in addition to GP referrals; the use,
or otherwise, of computerised support in assessing the
patient; the extension to internet services (possibly com-
bined with cameras);50 and the use of mobile ‘smart-
phone’ technology, for example, in rapid assessment of
musculoskeletal injuries. In particular, however, it will be
important to assess the costs and beneﬁts of services
once they are more established and provided on a wider
scale. The costs and beneﬁts of telehealth more gener-
ally need further exploration in relation to their cost
effectiveness particularly given the negative ﬁndings of
the Whole Systems Demonstrator project evaluating tele-
health support and treatment for patients with long-
term conditions.51 It would be helpful to identify those
characteristics that are likely to make services both more
cost-effective and less costly.
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